Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

Claire L. Langrish, Yi Chen, Wendy M. Blumenschein et al. · The Journal of Experimental Medicine · 2005 · 4K citations · Full text

Life Sciences, Cell Biology, Immunology +17

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

Jonathan Sherlock, Yi Chen, Craig A. Murphy et al. · Nature · 2003 · 2.9K citations

Life Sciences, Immunology, Neuroscience +14

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Dermatology, Immunology +14

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

Medicine, Dermatology, Immunology +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15